Bruce Downey of Barr Pharmaceuticals is leading the charge to create a legal framework for copies of biotech drugs. So far, the generic industry has gotten its wish list inscribed in a bill sponsored by congressional heavyweights. But the political battle about lowering the price of biotech drugs is far from over.
Bruce Downey is known in the pharmaceutical industry as the patent killer, and that’s not a compliment. The onetime U.S. Department of Justice attorney is the chairman and chief executive of Barr Pharmaceuticals Inc., the third-largest generic drug maker in the United States. Under his leadership, Barr has made millions in profits by successfully challenging patents on blockbuster drugs invented and manufactured by some of the world’s biggest pharmaceuticals companies. In 2005 Barr generated more than $750 million of its $1 billion worldwide revenues from manufacturing copycat versions of the drug industry’s biggest hits, including the popular antidepressant Prozac and breast cancer drug Tamoxifen.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
